Sensus Healthcare, Inc - SRTS STOCK NEWS

Sensus Healthcare, Inc. (Nasdaq: SRTS) has expanded its partnership with Colorado State University (CSU) by supplying a second SRT-100™ system for the study of superficial radiation therapy (SRT) in horses. This initiative takes place at CSU's Johnson Family Equine Hospital, aiming to investigate ophthalmic indications. With SRT showing promising results in earlier studies on other animals, the potential market for veterinary applications is significant, considering there are around 30,000 veterinary practices in the U.S. The CSU team hopes to publish their findings next year.

On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.

Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.

Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.

Sensus Healthcare (Nasdaq: SRTS) recently announced successful treatments using its SRT-100 system, demonstrating its capability in veterinary oncology. A mata mata turtle at Denver Zoo was treated for squamous cell carcinoma, showing no signs of the lesion three months post-therapy. This follows earlier treatments on various animals at Colorado State University, expanding the application of SRT in veterinary medicine. The ongoing partnership with CSU aims to develop protocols and clinical data, highlighting potential growth in a new market segment.

Sensus Healthcare (Nasdaq: SRTS), a medical device company, is set to present at two investment conferences in March 2022. The 34th Annual ROTH Conference will be held from March 13-15, with a key ‘Fireside Chat’ on March 15 at 9:30 a.m. PT. Investors can access the chat and a pre-recorded presentation on the company's website. Additionally, Sensus will participate in the Maxim 2022 Virtual Growth Conference on March 28-29, joining an Aesthetic Device Industry Panel on March 28 from 1:00 p.m. to 2:30 p.m. ET.

Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a share buyback program authorizing the purchase of up to $3,000,000 of its common stock. CEO Joe Sardano expressed optimism about the company's future and stated that the buyback is a strategy to enhance shareholder value. The program, which has no time limit, allows for purchases through various methods and is subject to management's discretion based on financial assessments and market conditions. Sensus specializes in non-invasive medical device treatments for cancer and other conditions.

Sensus Healthcare (Nasdaq: SRTS) has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash, completing the transaction on February 25, 2022. The sale allows Sensus to concentrate on its core dermatology business as it rebounds, utilizing proceeds to expand its dermatology product line, including new offerings like the TransDermal™ Infusion system and Laser Systems. This move aligns with Sensus's strategy to focus resources post-sale, which positions the company for growth in the dermatological segment.